20-F: Veraxa Biotech AG Completes Business Combination

Veraxa Biotech AG announces the completion of its business combination with Voyager Acquisition Corp., effective June 10, 2026, alongside significant financing updates.

Summary

• Veraxa Biotech AG (PubCo) has successfully completed its business combination with Voyager Acquisition Corp. (SPAC) on June 10, 2026.
• The transaction involved a merger between Veraxa Biotech AG and PubCo, with PubCo as the surviving entity.
• The company also secured significant financing, including a $27.5 million senior secured note from High Trail Capital (HTC) closing on June 15, 2026, and a $50 million at-the-market equity financing facility with Lincoln Park Capital Fund, LLC (LPC).
• The company's ordinary shares are listed on the Nasdaq Global Market under the symbol VRXA, and its warrants are listed on the Nasdaq Capital Market under the symbol VRXAW.
• The company reported operating losses of CHF 66.6 million for the year ended December 31, 2025, compared to CHF 28.1 million in 2024, with revenues of CHF 23,426 in 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant increase in operating losses and expenses, despite the successful completion of the business combination and securing new financing.

Positives

• Successful completion of the business combination with Voyager Acquisition Corp.
• Secured $27.5 million in senior secured financing from High Trail Capital.
• Established a $50 million at-the-market equity financing facility with Lincoln Park Capital Fund, LLC.
• The company's management believes it has sufficient liquidity to fund operations for at least the next twelve months.
• The company has a robust intellectual property portfolio with numerous patents and trademarks related to its core technologies.

Negatives

• Significant increase in general and administrative expenses, primarily due to stock-based compensation, rising by CHF 29.8 million in 2025.
• Research and development expenses increased by CHF 3.95 million in 2025, largely driven by stock-based compensation.
• Sales and marketing expenses also saw a substantial increase of CHF 3.3 million in 2025, primarily due to stock-based compensation.
• The company reported a net loss of CHF 66.6 million for the year ended December 31, 2025, a significant increase from CHF 28.1 million in 2024.
• A material weakness in internal control over financial reporting was identified due to a lack of financial reporting close controls.

Risks

• The company's future capital requirements depend on various factors, and it may not be able to raise additional financing on acceptable terms or at all.
• Forward-looking statements are subject to significant risks and uncertainties, including those described in the 'Risk Factors' section of the Prospectus.
• The company is an emerging growth company and has elected to not use the extended transition period for complying with new or revised financial accounting standards, which may make comparisons to other public companies more difficult.
• The company's ability to successfully develop, advance, and commercialize its pipeline of product candidates is subject to numerous risks, including clinical trial outcomes and regulatory approvals.
• Increased competition in the oncology and biotechnology industry could adversely affect the company's business.

Future Outlook

The company intends to raise additional capital through equity or debt fundraising activities to finance future operations and growth. Management believes it has sufficient liquidity to fund its planned operations and meet its obligations for at least the next twelve months.

Management Comments

• The company's goal is to establish a sustainable clinical pipeline of novel and differentiated oncology programs geared towards achieving superior efficacy while minimizing the burden of side effects for patients.
• The company's proprietary platform technologies enable the development of new generations of targeted cancer treatments and position it as a pioneer in creating highly effective, targeted antibody-based therapies for cancer patients.

Industry Context

StockSavvy.ai notes that Veraxa Biotech AG operates in the competitive oncology and biotechnology sector, focusing on antibody-based therapies. The company's strategy involves leveraging its proprietary platform technologies, including Click Chemistry ADC and BiTAC platforms, to develop next-generation cancer treatments. The recent business combination and financing activities are crucial for advancing its clinical pipeline, particularly its candidate VX-A901 for acute myeloid leukemia.

Corporate Governance

Related Party Transactions

• The company entered into a consulting services agreement with Xlife Sciences AG, a shareholder, for strategic and business development consulting.
• The company entered into a share lending agreement with Xlife Sciences AG for a fixed term ending June 30, 2026.
• The company entered into an unsecured loan agreement with Xlife Sciences AG for CHF 1,000,000, with a maturity date extended to September 30, 2026.

Stakeholder Impact

• Shareholders of Veraxa Biotech AG and Voyager Acquisition Corp. are now shareholders of the combined entity, Veraxa Biotech AG.
• Warrant holders of Voyager Acquisition Corp. now hold warrants to purchase PubCo Ordinary Shares.
• The significant increase in operating expenses, particularly stock-based compensation, may impact profitability and future shareholder value.
• The company's ability to secure future financing could impact its long-term viability and shareholder returns.

Next Steps

• Advance its clinical pipeline, including VX-A901 for acute myeloid leukemia.
• Continue to develop its proprietary platform technologies (Click Chemistry ADC and BiTAC).
• Utilize the secured financing to support future operations and growth.
• Implement remediation plans to address the material weakness in internal control over financial reporting.

Key Dates

Recommendation

While the completion of the business combination and securing of financing are positive developments, the significant increase in operating losses and expenses, coupled with a material weakness in internal controls, warrants a cautious approach. The company's future success hinges on its ability to advance its pipeline and manage its costs effectively. A 'hold' recommendation reflects the balance between the potential of its technology and the current financial and operational challenges.

Keywords

Veraxa Biotech AG, Voyager Acquisition Corp., Business Combination, Biotechnology, Oncology, ADC, T cell engagers, Nasdaq, Financing, SEC Filing, Form 20-F